SLRN vs. EWTX, LGND, MORF, DVAX, GMTX, AVDL, SUPN, XNCR, RCUS, and PCRX
Should you be buying Acelyrin stock or one of its competitors? The main competitors of Acelyrin include Edgewise Therapeutics (EWTX), Ligand Pharmaceuticals (LGND), Morphic (MORF), Dynavax Technologies (DVAX), Gemini Therapeutics (GMTX), Avadel Pharmaceuticals (AVDL), Supernus Pharmaceuticals (SUPN), Xencor (XNCR), Arcus Biosciences (RCUS), and Pacira BioSciences (PCRX). These companies are all part of the "pharmaceutical preparations" industry.
Edgewise Therapeutics (NASDAQ:EWTX) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, community ranking, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
Edgewise Therapeutics received 8 more outperform votes than Acelyrin when rated by MarketBeat users. However, 63.16% of users gave Acelyrin an outperform vote while only 62.50% of users gave Edgewise Therapeutics an outperform vote.
Acelyrin's return on equity of -29.09% beat Edgewise Therapeutics' return on equity.
Edgewise Therapeutics currently has a consensus target price of $31.20, suggesting a potential upside of 81.82%. Acelyrin has a consensus target price of $22.00, suggesting a potential upside of 443.21%. Given Edgewise Therapeutics' higher probable upside, analysts plainly believe Acelyrin is more favorable than Edgewise Therapeutics.
In the previous week, Acelyrin had 8 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 11 mentions for Acelyrin and 3 mentions for Edgewise Therapeutics. Acelyrin's average media sentiment score of 1.84 beat Edgewise Therapeutics' score of 0.96 indicating that Edgewise Therapeutics is being referred to more favorably in the media.
87.3% of Acelyrin shares are held by institutional investors. 24.1% of Edgewise Therapeutics shares are held by insiders. Comparatively, 13.6% of Acelyrin shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.
Summary
Edgewise Therapeutics beats Acelyrin on 9 of the 14 factors compared between the two stocks.
Get Acelyrin News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acelyrin Competitors List
Related Companies and Tools
